« Return to News | CROs/Service Providers

PRA Partners with Oncopartners in Brazil

Friday, January 29, 2010 07:57 AM

In an effort to speed up oncology trials in Latin America, PRA International entered into a partnership agreement with Oncopartners, a Latin American oncology development company, and its exclusive partner IBPC, a non-profit oncology research network made up of Brazil’s largest public oncology hospitals.

Under the terms of the agreement, the organizations will align operational processes to accelerate the planning, recruitment and startup of oncology trials. PRA and Oncopartners will also exclusively market each others’ services in the pre-award phase of the studies.

"As drug development timelines continue to be delayed globally due to lack of, or slow patient accrual, this alliance with Oncopartners and IBPC provides PRA with expanded access to patients and Brazil's leading investigators," said Kent Thoelke, PRA's senior vice president, scientific and medical affairs. "This partnership between Oncopartners and PRA will translate into faster study startup, more productive development process, and shorter overall clinical trial timelines for our clients."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.